Brii Biosciences Launches BRiSC siRNA Discovery Platform
Brii Biosciences launches BRiSC, a proprietary siRNA discovery platform designed to advance next-generation dual-targeting RNA medicines.
RNA-based Therapies | 17/10/2026 | By News Bureau | 150
Atrium Therapeutics receives a USD 15 million milestone payment from Bristol Myers Squibb under a global collaboration to develop innovative RNA-based therapies for cardiovascular diseases.
RNA-based Therapies | 24/04/2026 | By News Bureau | 169
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy